Related Experiment Video
Updated: Jul 26, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Methods for assessing endothelin ETA-receptor antagonists in preclinical studies
M Okada1, P K S Siegl, M Nishikibe
1Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Ibaraki, Japan.
Methods and Findings in Experimental and Clinical Pharmacology
|September 13, 2002
Summary
A novel nonpeptide compound acts as a potent, orally active, and long-lasting selective endothelin ETA-receptor antagonist. This discovery offers a promising therapeutic strategy for vasoconstrictive diseases like hypertension.
Area of Science:
- Pharmacology
- Cardiovascular Research
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in cardiovascular diseases.
- ET-receptor antagonists represent a potential therapeutic avenue for these conditions.
Purpose of the Study:
- To evaluate a novel compound as a selective ETA-receptor antagonist.
- To assess its in vitro and in vivo efficacy, selectivity, and pharmacokinetic properties.
Main Methods:
- Binding assays using CHO cells and tissue membranes.
- In vitro functional assays with isolated vessels.
- In vivo studies in rodent and canine models treated with ET-1.
Main Results:
- The compound demonstrated high selectivity for ETA receptors over ETB receptors.
- It exhibited potent vasoconstrictive blockade and favorable pharmacokinetics.
- Orally active and long-lasting effects were confirmed in animal models.
Conclusions:
- The developed nonpeptide compound is a potent, orally active, selective ETA-receptor antagonist.
- It shows significant potential for treating diseases associated with ET-1 activity.
